The Invicta Diagnostics IPO opening date is December 1, 2025, and the IPO will close on December 3, 2025. The Invicta Diagnostics IPO is a book-built issue. The company will raise approximately ₹28.12 crore through the IPO, which includes a fresh issue of ₹28.12 crore and an offer for sale of up to [.] equity shares with a face value of ₹10.
The price band for the Invicta Diagnostics IPO is ₹80 to ₹85 per share. The retail quota is 35%, QIB 50%, and HNI 15%. The Invicta Diagnostics IPO will be listed on the NSE on December 8, 2025. The allotment date for the Invicta Diagnostics IPO is December 4, 2025.
The company reported revenue of ₹30.18 crore in 2025, compared to ₹15.90 crore in 2024. The company reported a profit of ₹4.93 crore in 2025, compared to a profit of ₹3.81 crore in 2024. According to financials, IPO investors should apply for the IPO GMP for the long term.
Invicta Diagnostic SME IPO Details
| Issue Opening Date: | 1st Dec 2025 |
| Issue Closing Date: | 3rd Dec 2025 |
| Issue Price: | ₹80.00-85.00 Per Share |
| DRHP: | . |
| RHP: | . |
| IPO Listing At: | NSE SME |
| Issue Type: | Book Build Issue |
| Total Issue Size: | ₹28.12 Cr |
| Reserved for Market Maker: | ₹0.00 Cr |
| Net Issue Size: | ₹28.12 Cr |
| Fresh Issue: | ₹28.12 Cr |
| Face Value: | ₹10 Per Equity Share |
| Promoter Holding Pre IPO: | 90.52 |
Invicta Diagnostic IPO Market Lot
The Invicta Diagnostic IPO minimum market lot is 3,200 shares with ₹2,72,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 3,200 | ₹2,72,000 |
| Retail Maximum | 2 | 3,200 | ₹2,72,000 |
| S-HNI Minimum | 3 | 4,800 | ₹4,08,000 |
| S-HNI Maximum | 7 | 11,200 | ₹9,52,000 |
| B-HNI Minimum | 8 | 12,800 | ₹10,88,000 |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Invicta Diagnostic IPO Anchor Investors
| Anchor Bidding Date | November 28, 2025 |
| Anchor Investors List |  |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | January 4, 2025 |
| lock-in period end date 50% shares (90 Days) | March 3, 2025 |
Invicta Diagnostic IPO Dates
The Invicta Diagnostic IPO date is December 1 and the close date is December 3. The Invicta Diagnostic IPO allotment will be finalized on December 4 and the IPO listing on December 8.
| IPO Open Date: | December 1, 2025 |
| IPO Close Date: | December 3, 2025 |
| Basis of Allotment: | December 4, 2025 |
| Refunds: | December 5, 2025 |
| Credit to Demat Account: | December 5, 2025 |
| IPO Listing Date: | December 8, 2025 |
| IPO Bidding Cut-off Time: | December 3, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Dr. Ketan Jayantilal Jain, Dr. Sanket Vinod Jain, Rohit Prakash Srivastava, Badal Kailash Naredi and Jayesh Prakash Jain.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 92,63,173 | 91.89% |
| Promoter Holding Post Issue | 1,25,71,973 | -% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; and | ₹21.11 |
| General Corporate Purpose | ₹- |
Invicta Diagnostic IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2024 | ₹15.90 | ₹10.78 | ₹3.81 | ₹15.89 |
| 2025 | ₹30.18 | ₹23.62 | ₹4.93 | ₹21.22 |
| September 2025 | ₹17.08 | ₹11.65 | ₹4.08 | ₹34.90 |
Invicta Diagnostic IPO Valuation – FY2025
Check Invicta Diagnostic IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 44.28% |
| ROCE: | 42.00% |
| EBITDA Margin: | 30.57% |
| PAT Margin: | 16.38% |
| Debt to equity ratio: | 0.26 |
| Earning Per Share (EPS): | ₹5.86 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 36.25% |
| Net Asset Value (NAV): | ₹16.15 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Vijaya Diagnostic Centre Limited | 13.95 | 71.90 | 17.99% | 77.86 | – Cr. |
| Krsnaa Diagnostics Limited | 24.04 | 29.58 | 8.79% | 272.54 | – Cr. |
Incorporated in January 2021, Invicta Diagnostics Limited provides radiology and pathology solutions. The company offers pathology and radiology testing, including imaging, radiology, pathology, and teleradiology, through seven diagnostic centers and a central lab in Mumbai, Maharashtra, under the brand name 'PC Diagnostics'.
Invicta Diagnostics Limited (trading as PC Diagnostics) is a Mumbai-based diagnostic services company specializing in integrated pathology and radiology solutions. The company follows a hub-and-spoke model in the Mumbai Metropolitan Region, which includes:
A flagship hub in Thane West that provides full-spectrum pathology and advanced radiology (CT, MRI).
Three additional hubs (Bhayander, Byculla, Marol) that provide specialized diagnostic services.
Three spokes in Lower Parel, Sewri, and Kalwa focus on basic imaging (PET CT, X-ray, ultrasound) and sample collection. The company offers approximately 60 routine and 487 specialized pathology tests, as well as approximately 96 basic and 130 advanced radiology tests.
Invicta Diagnostics offers a comprehensive suite of diagnostic services, including:
Routine tests: These include CBC, lipid profiles, liver function tests (LFTs), kidney function tests (KFTs), and thyroid panels.
Special tests: These include molecular diagnostics, immunoassays, infectious disease markers (e.g., dengue, COVID-19), cancer markers, and genetic panels.
Sample collection network: Invicta utilizes phlebotomists and collection partners to reach patients at home or through its spoke centers.
As of October 31, 2025, the company had 157 permanent employees.
Competitive strengths:
Increasing its presence in the Mumbai Metropolitan Region (“MMR”), particularly in the radiology sector;
A diagnostics provider that offers a one-stop solution at an affordable price; technical capabilities and technology with IT infrastructure;
a dedicated management team with significant industry experience; and
implementation of a hub and spoke model.
IPO Lead Managers aka Merchant Bankers
- Socradamus Capital Pvt. Ltd.
Company Address
Invicta Diagnostic Ltd.
1 GF, Plot 217, Ambavat Bhavan
N.M Joshi Marg
Delisle Road
Mumbai, Maharashtra, 400013
Phone: 022 – 4971 0036
Email: investors@pcdiagnostics.in
Website: https://www.pcdiagnostics.in/
IPO Registrar
Bigshare Services Pvt.Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html